Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated

Hepatology

Volumn 43, Issue 3, 2006, Pages 401-404

  Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANABOLIC AGENT; ANDROGEN; BETA CATENIN; ESTROGEN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ORAL CONTRACEPTIVE AGENT; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; UVOMORULIN;

CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE SEVERITY; EDITORIAL; GENE MUTATION; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER HEMORRHAGE; MALIGNANT TRANSFORMATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADENOMA, LIVER CELL; BETA CATENIN; HUMANS; LIVER NEOPLASMS; MUTATION; PROGNOSIS;

EID: 33645222607     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21110     Document Type: Editorial

References (34)

1. Belghiti J, Pateron D, Panis Y, Vilgrain V, Flejou JF, Benhamou JP, et al. Resection of presumed benign liver tumours. Br J Surg 1993;80:380-383.
2. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005;39:401-412.
3. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992;12:73-79.
4. Taylor W. Risk factors associated with the use of sex hormones. Anticancer Res 1987;7:943-948.
5. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002;161(Suppl 1):S46-S49.
6. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21:877-892; discussion 892-874.
7. Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Metreau JM, Meignan M, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. HEPATOLOGY 1995;22:1674-1681.
8. Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000;216:395-402.
9. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988;208:558-564.
10. Mentha G, Rubbia-Brandt L, Howarth N, Majno P, Morel P, Terrier F. Management of focal nodular hyperplasia and hepatocellular adenoma. Swiss Surg 1999;5:122-125.
11. Zucman-Rossi J, Jeannot E, Tran Van Nhieu J, Scoazec J-Y, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. HEPATOLOGY 2006;43:515-524.
12. Torbenson M, Lee JH, Chot M, Gage W, Abraham SC, Montgomery E, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wm signaling pathway. Mod Pathol 2002;15:189-196.
13. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001;61:2085-2091.
14. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-2071.
15. Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001;61:3245-3249.
16. Hussain SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga SP. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004;292:157-169.
17. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, Monga SP. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004;126:1134-1146.
18. Monga SP, Micsenyi A, Germinaro M, Apte U, Bell A. beta-Catenin regulation during matrigel-induced rat hepatocyte differentiation. Cell Tissue Res 2006;323:71-79.
19. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003;124:202-216.
20. Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. HEPATOLOGY 2001;33:1098-1109.
21. Sodhi D, Micsenyi A, Bowen WC, Monga DK, Talavera JC, Monga SP. Morpholino oligonucleotide-triggered beta-catenin knockdown compromises normal liver regeneration. J Hepatol 2005;43:132-141.
22. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo JH, Ranganathan S, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005;129:285-302.
23. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999;21:1021-1030.
24. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-273.
25. Ogawa K, Yamada Y, Kishibe K, Ishizaki K, Tokusashi Y. Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 1999;59:1830-1833.
26. Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol 2005;8:435-447.
27. Ban KC, Singh H, Krishnan R, Seow HF. GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 2003;199:201-208.
28. Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000;152:45-51.
29. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155:703-710.
30. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21:4863-4871.
31. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004;101:17216-17221.
32. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127:1110-1122.
33. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res 2001;61:4445-4449.
34. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004;4:653-671.